 The FDA has instituted a clinical hold on Sigilon Therapeutics Incs NASDAQ: SGTX Phase 12 study of SIG-001 in patients with severe or moderately severe hemophilia A. The clinical hold was initiated following the Companys submission of a serious adverse event SAE and temporary enrollment halt to the FDA and other regulatory agencies. 